190 related articles for article (PubMed ID: 22543678)
1. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
[No Abstract] [Full Text] [Related]
2. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
Bajetta E
Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
[No Abstract] [Full Text] [Related]
3. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
Ammoury AF; El Sayed F; Bazex J
Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
[No Abstract] [Full Text] [Related]
4. A lupus-like reaction to subcutaneous interferon-α at injection sites.
Chodkiewicz HM; Cohen PR; Kim KB; Ivan D; Gershenwald JE
J Drugs Dermatol; 2012 Mar; 11(3):393-8. PubMed ID: 22395592
[TBL] [Abstract][Full Text] [Related]
5. [Vitiligo and morphea: autoimmune cutaneous side effects of interferon treatment].
Martínez-García S; Fernández-Ballesteros MD; Segura-Palacios JM
Actas Dermosifiliogr; 2012 Apr; 103(3):250-1. PubMed ID: 22056259
[No Abstract] [Full Text] [Related]
6. A Case of Perforating Folliculitis Induced by Vemurafenib.
Shiraishi K; Masunaga T; Tohyama M; Sayama K
Acta Derm Venereol; 2019 Feb; 99(2):230-231. PubMed ID: 30281138
[No Abstract] [Full Text] [Related]
7. Mediastinal sarcoidosis induced by high-dose alpha-2-interferon therapy in a patient with malignant melanoma.
Massaguer S; Sánchez M; Castel T
Eur Radiol; 2004 Sep; 14(9):1716-7. PubMed ID: 14740162
[No Abstract] [Full Text] [Related]
8. Intertriginous and follicular eruption to anticytotoxic T-lymphocyte antigen 4 monoclonal antibody.
Lim JL; Dahiya M; Burgin S
J Am Acad Dermatol; 2008 Aug; 59(2 Suppl 1):S60-1. PubMed ID: 18625394
[No Abstract] [Full Text] [Related]
9. Meyerson's naevi induced by interferon alfa plus ribavirin combination therapy in hepatitis C infection.
Conde-Taboada A; de la Torre C; Feal C; Mayo E; Gonzalez-Sixto B; Cruces MJ
Br J Dermatol; 2005 Nov; 153(5):1070-2. PubMed ID: 16225630
[No Abstract] [Full Text] [Related]
10. [To outwit melanoma with its own tricks].
Bischoff A
MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
[No Abstract] [Full Text] [Related]
11. Early signs of liver failure after low-dose interferon alfa-2b for cutaneous melanoma.
Ammoury A; El Sayed F; Farah C; Bazex J
J Am Acad Dermatol; 2008 Mar; 58(3):532-3. PubMed ID: 18280369
[No Abstract] [Full Text] [Related]
12. Interleukin-2-associated bullous drug dermatosis.
Hofmann M; Audring H; Sterry W; Trefzer U
Dermatology; 2005; 210(1):74-5. PubMed ID: 15604553
[No Abstract] [Full Text] [Related]
13. Meyerson's phenomenon induced by interferon-alfa plus ribavirin in hepatitis C infection.
Girard C; Bessis D; Blatìre V; Guilhou JJ; Guillot B
Br J Dermatol; 2005 Jan; 152(1):182-3. PubMed ID: 15656829
[No Abstract] [Full Text] [Related]
14. [Cutaneous necrosis due to interferon alpha in a patient with melanoma].
Aguilar García G; Serrano Falcón C; Serrano Falcón Mdel M; Carmona MD; Linares Solano J; Serrano Ortega S
Actas Dermosifiliogr; 2006 Oct; 97(8):539-42. PubMed ID: 17067536
[TBL] [Abstract][Full Text] [Related]
15. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.
Agarwala SS; Gray RJ; Wong MK
J Clin Oncol; 2009 Sep; 27(25):e82-3; author reply e84. PubMed ID: 19635995
[No Abstract] [Full Text] [Related]
16. Livedo reticularis: a side effect of interferon therapy in a pediatric patient with melanoma.
Fox M; Tahan S; Kim CC
Pediatr Dermatol; 2012; 29(3):333-5. PubMed ID: 21575046
[TBL] [Abstract][Full Text] [Related]
17. Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
Vallés L; González M; Polo I; Enguita AB; Vanaclocha F; Ortiz-Romero PL
Arch Dermatol; 2009 Jan; 145(1):98-9. PubMed ID: 19153363
[No Abstract] [Full Text] [Related]
18. Vemurafenib sensitivity skin reaction after ipilimumab.
Harding JJ; Pulitzer M; Chapman PB
N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
[No Abstract] [Full Text] [Related]
19. Skin necrosis revealing antiphospholipid syndrome during immunotherapy for melanoma.
Gressier L; Guilpain P; Gorin I; Carlotti A; Goulvestre C; Boitier F; Guillevin L; Avril MF; Mouthon L; Dupin N
Acta Derm Venereol; 2010 Jul; 90(4):433-4. PubMed ID: 20574622
[No Abstract] [Full Text] [Related]
20. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]